Background
The metabolic alterations of cancer cells represent an opportunity for developing selective antineoplastic treatments. We investigated the therapeutic potential of ST1326, an inhibitor of carnitine-palmitoyl transferase 1A (CPT1A), the rate-limiting enzyme for fatty acid (FA) import into mitochondria.
Methods
ST1326 was tested on in vitro and in vivo models of Burkitt's lymphoma, in which c-myc, which drives cellular demand for FA metabolism, is highly overexpressed. We performed assays to evaluate the effect of ST1326 on proliferation, FA oxidation, and FA mitochondrial channeling in Raji cells. The therapeutic efficacy of ST1326 was tested by treating Eµ-myc mice (control: n = 29; treatment: n = 24 per group), an established model of c-mycmediated lymphomagenesis. Experiments were performed on spleen-derived c-myc-overexpressing B cells to clarify the role of c-myc in conferring sensitivity to ST1326. Survival was evaluated with Kaplan-Meier analyses. All statistical tests were two-sided.
Results
ST1326 blocked both long-and short-chain FA oxidation and showed a strong cytotoxic effect on Burkitt's lymphoma cells (on Raji cells at 72 hours: half maximal inhibitory concentration = 8.6 μM). ST1326 treatment induced massive cytoplasmic lipid accumulation, impairment of proper mitochondrial FA channeling, and reduced availability of cytosolic acetyl coenzyme A, a fundamental substrate for de novo lipogenesis. Moreover, treatment with ST1326 in Eµ-myc transgenic mice prevented tumor formation (P = .01), by selectively impairing the growth of spleen-derived primary B cells overexpressing c-myc (wild-type cells + ST1326 vs Eµ-myc cells + ST1326: 99.75% vs 57.5%, difference = 42.25, 95% confidence interval of difference = 14% to 70%; P = .01).
Conclusions
Our data indicate that it is possible to tackle c-myc-driven tumorigenesis by altering lipid metabolism and exploiting the neoplastic cell addiction to FA oxidation. J Natl Cancer Inst;2013;105: [489] [490] [491] [492] [493] [494] [495] [496] [497] [498] Changes in cellular metabolism and the increased demand for intermediate metabolites and precursors for protein, lipid, and nucleotide synthesis are prerequisites for the invasive, metastatic, and adaptive properties of cancer cells (1) (2) (3) . These metabolic programs may be dictated by specific oncogenic activities. For example, several studies support a direct role for c-myc on mitochondrial functions by indicating that c-myc not only promotes glycolysis but also enhances the ability of mitochondria to use nonglucose substrates, which is essential for the production of cellular metabolic intermediates (2, (4) (5) (6) (7) . Metabolic changes are therefore an optimal target for the development of cancer management therapies (8, 9) . Indeed, a number of inhibitors affecting metabolic pathways have already been tested as anticancer agents and are presently undergoing various stages of preclinical and clinical studies (10) (11) (12) (13) (14) (15) (16) (17) (18) .
In addition, multiple lines of evidence have documented how fatty acid (FA) synthesis is an important element in cancer cell survival and progression (19) (20) (21) , being sustained by mitochondrial function to produce cytosolic acetyl coenzyme A (acetyl-CoA. The acetyl group of acetyl-CoA is the requisite building block for the endogenous synthesis of FA, cholesterol, and isoprenoids (22) and for the acetylation reactions that modify proteins (23) . Acetyl groups can leave mitochondria in the form of citrate by tricarboxylate transport. In the cytosol, citrate is cleaved by ATP citrate lyase, both to produce cytosolic acetyl-CoA and to regenerate oxaloacetate. To a lesser extent, the oxidative metabolism-derived mitochondrial acetyl-CoA is converted into acetyl-L-carnitine by carnitine acetyltransferase (CAT) before being transported into cytosol by carnitine/acylcarnitine translocase (CACT) (24) .
Some evidence of mitochondrial FA metabolism blockade as a therapeutic approach against cancer already exists and includes the inhibition of carnitine palmitoyltransferase type 1 (CPT1), a mitochondrial enzyme involved in FA channeling inside mitochondria for β-oxidation. Three different isoforms of CPT1 have been identified (CPT1A, CPT1B, and CPT1C), which are differently distributed in organs and tissues (25, 26) . Several studies have demonstrated that etomoxir, a powerful irreversible inhibitor of both CPT1A and B, was able to induce the antiproliferative effect either alone or in combination with genotoxic and nongenotoxic drugs (27, 28) . To circumvent undesired side effects of etomoxir outside the liver-in particular in the heart, which contains mostly CPT1B and only very low levels of CPT1A isoforms (26)-reversible inhibitors were developed with CPT1A-specific affinity (29) . ST1326 is an aminocarnitine derivative, which has been shown to selectively inhibit CPT1A in isolated rat mitochondria (30, 31) . This compound has been widely studied for the treatment of type 2 diabetes mellitus, in which it caused a pronounced reduction of serum glucose levels when administered orally in murine models of type 2 diabetes (30). Furthermore, ST1326 was shown to elicit an anorexiant effect and to inhibit endogenous glucose production after being centrally administered to rats (32) . So far there is no information about the possible effects of ST1326 on cancer cells.
Considering that the isoform present in lymphocytes is CPT1A (33), the target specificity of ST1326, and recent reports showing that c-myc overexpression drives the mitochondrial production of acetyl-CoA (34), we hypothesized that the study of c-myc-overexpressing lymphoblastoid tumors could offer a good model for the development of new anticancer treatments targeting lipid metabolism. Thus we studied the effect of ST1326 in a well-defined in vitro and in vivo model of B cell Burkitt's lymphoma.
Methods

Cell Cultures and Drug Treatments
For this study, we used c-myc-overexpressing human Burkitt's lymphoma cell lines (Raji and Daudi), Epstein-Barr virus-immortalized, untransformed, lymphoblastoid cell lines (AG3138A and GM130C), and murine spleen-derived primary B cells. All cell lines were cultured and pharmacologically treated as described in the Supplementary Methods (available online).
Cytotoxic Assays
The cytotoxic effect of ST1326 was evaluated by counting both viable and dead cells for any condition every 24 hours after Trypan blue vital staining. We assumed the viability of untreated cells as 100% at any time and calculated the relative percentage of viability in ST1326-treated cells for all cell lines. The half maximal inhibitory concentration (IC 50 ) values were extrapolated from three independent experiments using both nonlinear regression (curve fit) analysis and the sigmoidal dose-response equation with Prism program version 5.0a (GraphPad Software Inc, La Jolla, CA). We chose the concentration of 10 μM for further experiments on Raji cells because this is quite similar to the calculated ST1326 IC 50 at 72 hours.
Mitochondrial Isolation
Raji cells were collected and processed for the preparation of mitochondria as previously indicated (35) . The functional integrity of isolated mitochondria was assessed as described in the Supplementary Methods (available online).
Enzymatic Determinations CPT1, CACT, and CAT activities, the incorporation of radiolabeled carnitine into acylcarnitine, and the sensitivity of CPT1 to malonyl-CoA inhibition were assayed in Raji cells according to previously described and optimized methods (35) (36) (37) (38) (39) . For more details, see the Supplementary Methods (available online).
Measurement of FA Oxidation and Analysis of
Acylcarnitine Intermediates in ST1326-Treated Cells FA total oxidation was measured as reported previously (35, 36) . Analysis of the acylcarnitine profile was performed by mass spectrometry as previously described (40) . Further details can be found in the Supplementary Methods (available online).
Lipogenesis
De novo lipogenesis was determined as previously described (41) To determine the incorporation of the label into total lipids, the culture medium was removed and cells were washed twice in 2 mL of ice-cold PBS before harvest in 1 ml of PBS and centrifuged at 18 000 g for 2 minutes at 4°C. Cell pellets were resuspended in 80 µL of PBS, and total lipids were extracted using the method of Bligh and Dyer (42) . Dried lipids were resuspended in 200 μL of chloroform to determine the radioactive content.
Assessment of ATP Levels
ATP levels were determined after 8, 24, 48, and 72 hours of treatment with ST1326 10 μM. We pelleted and lysed 1 × 10 5 cells according to the manufacturer's instructions and measured the luminescence for 2 seconds of integration time in a GloMax 20/20 Luminometer (Promega, Milan, Italy). ATP concentrations were extrapolated from a logarithmic standard curve obtained by measuring the bioluminescence of a serial dilution of the ATP standard reagent supplied with the assay kit. The standard curve was performed for each experiment, and the coefficient of variation for its linearity was 0.031. ATP level evaluations were performed on three independent experiments.
Real Time Polymerase Chain Reaction
Gene expression assays were performed according to standard realtime polymerase chain reaction analysis (Supplementary Methods, available online). For each assay, we performed three experiments in triplicate.
Western Blots
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting were carried out according to standard procedures Downloaded from https://academic.oup.com/jnci/article-abstract/105/7/489/911627 by guest on 27 February 2019 using 15 μg of total protein extracts and in triplicate. Antibodies were mouse monoclonal anti-c-myc (1:500; Calbiochem, Darmstadt, Germany), rabbit polyclonal anti-AMPKα1/2 and anti-phospho-AMPKα1 (Thr172) (1:400; Santa Cruz Biotechnology, Heidelberg, Germany), and mouse monoclonal anti-β-actin (1:4000; SigmaAldrich, Milan, Italy).
Boron-Dipyrromethene (BODIPY 493/503) Staining and Visualization
BODIPY 493/503 (1 mg/mL) was provided by Invitrogen (Milan, Italy) and applied at 1 µg/mL in PBS on fixed cells following the manufacture's procedure. Briefly, after ST1326 treatment cells were fixed in 1% paraformaldehyde for 10 minutes at 4°C, they were washed with PBS and then stained with BODIPY493/503 dye at a concentration of 1 μg/mL for 20 minutes at 4°C. Cells were then mounted and coverslipped. The staining procedure was conducted in triplicate samples.
Histomorphological Analysis
Mitochondria were stained by incubating cells with 500 nM MitoTracker Red CMXRos (Molecular Probes, Milan, Italy). For CPT1A staining, cells were fixed and processed as described in the Supplementary Methods (available online).
For hematoxylin and oil red O staining on Raji cells, cells were spotted on glass slides. Slides were processed following standard protocols.
For transmission electron microscopy analysis, cells were pelleted, fixed in Karnovsky, and processed as described in the Supplementary Methods (available online).
In Vivo Experiments
Severe combined immunodeficient and Eµ-myc mice were housed with ad libitum access to standard diet and water, maintained on a 12-hour light/dark cycle at 21°C room temperature, and killed with an anesthetic overdose according to the approved experimental protocol. Animal experiments were performed in compliance with the Bologna University Ethical Committee guidelines on animal research (protocol approval reference 12511-X/10).
We established the effective dose of ST1326 in preventing tumor onset on 25 severe combined immunodeficient (B-cell-and T-cell-deficient) female mice (Charles Rivers Italia, Milan, Italy) aged 6 weeks that were xenografted with 5 × 10 6 Raji cells and treated with different doses of the drug. After that we evaluated the antineoplastic effect of ST1326 on C57BL/6 Eµ-myc mice, a wellcharacterized model of c-myc-mediated lymphomagenesis (43, 44) . Fifty-three transgenic Eµ-myc mice were randomly divided into two groups, treated starting from the fourth week of age either with vehicle physiological solution (number of mice = 29; 13 males and 16 females) or with ST1326 30 mg/kg/day (number of mice = 24; 11 males and 13 females) intraperitoneally for 21 consecutive days and observed until the 40th week of age. Mice were killed at the first symptoms of disease.
For spleen evaluation, six wild-type and six transgenic male Eµ-myc mice were randomly divided into two groups (n = 3 per group) and treated starting from the fourth week of age either with vehicle solution or with ST1326 30 mg/kg/day intraperitoneally for 21 consecutive days. After treatment, mice were killed, and spleens were recovered and processed for immunohistochemical studies. The excised spleens from wild-type and Eµ-myc mice were fixed in buffered formalin, dehydrated in a decreasing series of ethanol, and paraffin embedded. Sections that were 3 µm thick were used for the morphological and immunohistochemical analysis.
Statistical Analysis
Data were analyzed using Prism software version 5.0a. KaplanMeier estimates and the log-rank (Mantel-Cox) test were used for the comparisons among survival curves. The Student t test was used for comparisons between two groups. IC 50 values were extrapolated from three independent experiments using both nonlinear regression (curve fit) analysis and the sigmoidal dose-response equation with Prism software. P values less than.05 were regarded as statistically significant. All statistical tests were two-sided.
results
Effect of CPT1 Inhibitor ST1326 on Human Burkitt's Lymphoma Cell Lines
To evaluate the antiproliferative action of ST1326, we verified the presence and the mitochondrial localization of its specific target, CPT1A, in Raji cells ( Figure 1A ) and evaluated the inhibitory effect of ST1326 on CPT1A activity at different doses ( Figure 1B ). The treatment hindered Raji cell growth in a dose-dependent manner ( Figure 1C ). The cytotoxic activity of ST1326 was then assayed in both c-myc-overexpressing cell lines (Raji and Daudi) and in EpsteinBarr virus-immortalized, untransformed, lymphoblastoid cell lines (GM130C and AG3138A), which express a low level of c-myc. Each cell line was exposed to ST1326 for up to 96 hours at different concentrations. The obtained IC 50 values showed a different sensitivity to ST1326 for each line as well as a greater sensitivity of the transformed cells. These differences were statistically significant when compared with Raji IC 50 value (see Figure 1D ) (IC 50 after 72 hours of treatment: Raji vs GM130C: 8.6 μM vs 47 μM, difference = −38.4 μM, 95% confidence interval [CI] = −41.45 μM to −35.35 μM, P < .001; Raji vs AG3138A: 8.6 μM vs 21 μM, difference = −12.40 μM, 95% CI = −15.10 μM to −9.695 μM, P < .001) ( Figure 1D ). Therefore, we chose Raji cells as an in vitro model and used ST1326 at 10 μM.
Effect of ST1326 on FA Metabolism
We hypothesized that the cytotoxic effect of ST1326 might be due to a defect in energy production and/or intermediary products of oxidative metabolism caused by the blockade of FA oxidation. Metabolic studies were carried out in Raji cells in the presence or absence of ST1326. Oxidation of exogenous FA was measured following the oxidation of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C] palmitate, therefore evaluating labeled carbon dioxide (CO 2 ) and acid-soluble metabolites derived from acetyl-CoA processing. The total oxidation of FA is the sum of the metabolism toward acid-soluble metabolites and CO 2 . We found that total [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]palmitate oxidation was reduced by ST1326 treatment in a dose-dependent manner, whereas the difference between treated cells and controls was statistically significant (ST1326 10 μM: 7.08 vs 1.68 nmol/h/mg protein, difference = 5.4, 95% CI = 3.005 to 7.795, P = .003; ST1326 20 μM: 7.08 vs 1.44 nmol/h/mg protein, difference = 5.64, 95% CI = 3.141 to 8.139, P = .003) (Figure 2A, top panel) . Consequently, CO 2 production and, in particular, acid-soluble metabolites formation were statistically significantly lower in ST1326-treated cells than in those from controls (CO 2 : 2.12 vs 0.60 nmol/h/mg protein, difference = 1.52, 95% CI = 0.004 to 3.036, P = .049; acid-soluble metabolites: 5.20 vs 1.24 nmol/h/mg protein, difference = 3.96, 95% CI = 2.889 to 5.031, P < .001) (Figure 2A, lower panel) . Note that the inhibition of FA oxidation in ST1326-treated cells is associated with the decrease in CPT1A activity ( Figure 1B) .
To evaluate the contribution of FA oxidation inhibition on cell energy, the total ATP levels were measured in the Raji cells treated with ST1326. Surprisingly, we found that the treatment did not cause a depletion of cytosolic ATP levels ( Figure 2B ), which proved to be higher in treated Raji cells than in untreated cells, especially after short-term treatment. The ATP increase was statistically significant after 8 hours (P = .047), 48 hours (P = .02), and 72 hours (P = .004) of treatment (CTR vs ST1326 at 72 hours: 1.000 vs 2.563, difference = −1.563, 95% CI = −2.308 to −0.8184). This effect might very well depend on an early response to treatment that blocks cellular energy consuming anabolic pathways. These results were confirmed by the analysis of the phosphorylation status of the ''energy sensor'' AMP-activated kinase (AMPK), which is activated by an increase in the cellular AMP/ATP ratio. In accordance with ATP level assay, the levels of Thr172-phosphorylated AMPK (p-AMPK) were not increased in ST1326-treated cells, thus indicating that the cells were not in an energy-requiring condition (AMPK vs p-AMPK in ST1326: 0.7963 vs 0.6779, difference = 0.1183, 95% CI = 0.0589 to 0.1778, P = .005) ( Figure 2C ). Altogether, these observations suggest that the ST1326 cytotoxic effect is not due to the inhibition of energy production mechanisms.
Interestingly, we observed that ST1326-treated cells became larger than untreated cells, with the increased cell size proportional to the length of the treatment (size after 72 hours of treatment for CTR vs ST1326: 108.5 µm 2 vs 302.1 µm 2 , difference = −193.6 µm 2 , 95% CI= −247.4 µm 2 to −139.8 µm 2 , P < .001). We analyzed cell morphology after 72 hours of ST1326 treatment by hematoxylin stain, which denoted the presence of peripheral nuclei, an altered nucleus/cytoplasm ratio, and abundant cytoplasm ( Figure 3A, top) and sometimes revealed the presence of multinucleated cells. Cell cycle analysis confirmed an accumulation of ST1326-treated cells in G2-M phases as compared with controls (G1: 40% vs 25.56%, difference = 14.44%, 95% CI = 10.25% to 18.75%, P < .001; G2-M: 20.95% vs 37.46%, difference = −16.51%, 95% CI = −20.32% to −12.72%, P < .001), which was not followed by an increase in the proliferation rate (Supplementary Figure 1A, available online) . The staining of lipids by oil red O revealed that cytoplasms were rich in lipid droplets, which progressively increased with the duration of ST1326 exposure ( Figure 3A, bottom) . Transmission electron microscopy revealed that lipid accumulation occurred early and was related to the length of treatment. Furthermore, transmission electron microscopy analysis also showed alterations in the 
Effect of ST1326 Treatment on De Novo Lipogenesis by Acetate or Glucose
The [ 14 C]acetate incorporation into intracellular lipids assessed over a short period of time provides a measure of net de novo lipogenesis. When assessed over 3 hours, no differences were observed after treatment with ST1326. However, when cells were incubated with 
Effect of ST1326 on Mitochondrial Channeling and Cytosolic Acylcarnitine Profile
To further characterize the biochemical effect of ST1326 leading to lipid accumulation, we evaluated the activity of CAT and CACT, two key enzymes that are essential for the modification of acyl-CoA and their entry into the mitochondrion. Our data demonstrated that ST1326 inhibits FA oxidation not only by blocking CPT1A ( Figure 1B ) but also by inhibiting CACT activity ( Figure 5A ). Conversely, we did not observe any apparent decrease in CAT activity ( Figure 5B) . A more comprehensive assessment of mitochondrial metabolism was performed by using mass spectrometry-based acylcarnitine profiling. Acylcarnitine metabolites are generated as byproducts of incomplete substrate catabolism and, 14 C]palmitate into nmol/h/mg, correspond to means ± 95% confidence intervals of three different experiments. B and C) Treatment with ST1326 did not reduce energy production in Raji cells compared with control (CTR) cells as documented by ATP levels evaluated after 8 hours (P = .047), 24 hours (not significant), 48 hours (P = .02), and 72 hours (P = .004) of ST1326 (10 μM) incubation (B) and the reduced level of phospho-AMP-activated kinase (p-AMPK) in respect to total AMPactivated kinase (AMPK) (P = .005) (C); this enzyme undergoes phosphorylation only in energy requirement status (low ratio AMP/ATP). The results in (B) and (C) correspond with means ± 95% confidence intervals of three different experiments. *P < .05, statistically significantly different from control, and calculated using two-sided Student t test.
therefore, can indicate shifts in fuel selection and/or flux limitations in specific mitochondrial enzymes (45) .
In response to palmitate exposure, Raji cells showed a metabolic switch favoring higher rates of β-oxidation and lower degradation of amino acids, as documented by both the global increase in most lipid-derived acylcarnitines ( Figure 5C ; Supplementary  Figure 2 , available online) and the reduction in species deriving exclusively from amino acids (odd-chain acylcarnitines, C3 and C5) (Supplementary Figure 2, available online) . Conversely, the samples collected from ST1326-treated cells displayed the opposite behavior (considering FA vs FA + ST1326: C2 = 10.50 vs 1.30 nmol/ mg protein, difference = 9.2, 95% CI = 6.106 to 11.58, P < .001; C4 = 0.51 vs 0.14 nmol/mg, difference = 0.37, 95% CI = 0.143 to 0.597, P = .01; C5 = 1.83 vs 3.58 nmol/mg, difference = −1.75, 95% CI = −1.397 to −0.943, P < .001), thus strongly suggesting a sizable increase in the branch chain amino acid oxidation. Interestingly, the ST1326 treatment causes a statistically significant decrease in acetylcarnitine C2 deriving from mitochondrial acetyl-CoA, the universal end product of glucose, FA, and amino acid catabolism, which, in turn, fuels the tricarboxylic acid cycle (35) . Thus the C2 decrease in ST1326-treated cells suggests not only a lower degradation of FA substrates, which can be ascribed to inhibited CPT1A activity, but also a perturbation in the export of C2 from mitochondria to the cytosol due to impaired CACT.
Effect of ST1326 Treatment on Lymphomagenesis in Eµ-myc Mice
To test the in vivo therapeutic potential of ST1326, we established the effective dose for preventing the onset of tumors in severe combined immunodeficient mice xenografted with Raji cells and then performed a new series of experiments in transgenic Eµ-myc mice. On average, 50% of these mice spontaneously develop aggressive B-cell lymphomas resembling the molecular features of Burkitt's lymphoma within the 14th to 16th week of age. The survival curves ( Figure 6A ) showed a statistically significant delay in the onset of lymphomas in treated mice compared with the control group (P = .01), thus resulting in disease escape for 45.8% of them at the 40th week. These results demonstrated a strong efficacy of ST1326 in preventing lymphomagenesis in vivo.
Because mice the treatment was administered before tumor onset in Eµ-myc, our results suggest that ST1326 may have an effect on myc-overexpressing cells independently of neoplastic transformation. To confirm this hypothesis, we analyzed the spleens of Eµ-myc transgenic mice and their wild-type littermates immediately after the treatment with ST1326 30 mg/kg/ day intraperitoneally for 21 days. Although this treatment did not change the gross features of the spleen of transgenic mice (Supplementary Figure 3 , available online), we observed a strong effect on their microscopic architecture. In particular, the B-cell hyperplasia, which disrupts the morphology of lymphatic nodules in the white pulp of the Eµ-myc mice, was dramatically reduced after ST1326 treatment ( Figure 6B ). In addition, the anomalous presence of B cells in the red pulp observed in transgenic mice was also greatly reduced in treated mice ( Figure 6B ). To gain further insight, we isolated B cells from the spleen of Eµ-myc mice and wild-type controls aged 5 weeks and exposed them to ST1326 treatment ex vivo. B cells purified from Eµ-myc transgenic mice were more sensitive to ST1236 than those purified from their wildtype littermates (WT + ST1326 vs Eµ-myc + ST1326: 99.75% vs 57.5%, difference = 42.25%, 95% CI =14% to 70%, P = .01) Figure 6C ), thus indicating that myc overexpression is sufficient for increasing the cellular sensitivity to the cytotoxic action of ST1326.
Discussion
The results of this study suggest that the pharmacological inhibition of FA oxidation and trafficking of both short-and longchain fatty acyl groups through the mitochondrial membranes have a dramatic impact on cancer cell survival, resulting in an inhibition of tumor cell proliferation in in vitro and in vivo models of Burkitt's lymphoma.
Our results are consistent with several reports emphasizing the contribution of FA metabolism and, more specifically, increased FA oxidation in tumorigenesis (21, (46) (47) (48) (49) (50) . Conversely, it has recently been shown that enhanced FA catabolism is linked to chemoresistance (51) and that pharmacologically inhibiting FA oxidation induces apoptosis in cancer cells (27) . Because CPT1 is the "rate-limiting" enzyme of FA oxidation (52), a majority of studies have targeted this protein to decrease β-oxidation rate in tumors.
Nevertheless, it is important to stress that all compounds for which data have been reported are nonselective inhibitors and affect more than one isoform of CPT1. For this reason it is important to select inhibitors that mainly act on CPT1A (expressed in lymphoblastoid tumor cells and liver) to avoid known or unknown C) The 24-hour lipid exposure determined acylcarnitine accumulation in Raji cells, which did not occur when fatty acids (FAs) were incubated in combination with ST1326 10 μM. Raji cells were pretreated for 24 hours with 0.5% bovine serum albumine (BSA) alone or complexed with 400 μM palmitate plus 500 μM carnitine in the absence or presence of ST1326 10 μM. Data represent the mean ± 95% confidence interval from experiments performed in triplicate. These are representative experiments from at least three others with similar results. *P < .05, calculated using a two-sided Student t test.
off-target effects due to the inhibition, in particular, of CPT1B (expressed at high levels in heart and skeletal muscles). Unlike etomoxir, the aminocarnitine derivative ST1326 has shown a notable inhibitory activity on CPT1A, with slight effects on CPT1B, whereas the toxic effects on the liver are transient (27).
ST1326 showed a powerful cytotoxic activity, reduced the CPT1 activity, and selectively blocked the FA oxidation, which was not associated with low energy production. Thus we may suppose that the first response to the FA oxidation inhibition could be the interruption of the majority of the energy-consuming anabolic cellular pathways. Cell toxicity is instead associated with an increased accumulation of lipids detectable very early after treatment (see Supplementary Figure 1 , available online). Furthermore, transmission electron microscopy analysis revealed anomalous mitochondria and an abundant presence of degenerated lysosomes and myelinic figures indicating that cells, while they are accumulating lipids, lose the ability to assemble lipids for regenerating plasma and organelle membranes.
To study at what level ST1326 inhibits FA oxidation, causing lipid accumulation, we evaluated CAT and CACT activity. The data obtained demonstrated that ST1326 blocks not only CPT1 but also CACT activity, the enzyme responsible for the transport of acetyl-carnitine in the cytoplasm, where it regenerates acetylCoA and carnitine. Thus the inhibition of CPT1 and CACT induces a complete block of FA oxidation, a massive depletion of cytosolic acetyl-CoA derived from acetyl-carnitine or citrate, and an increase in mitochondrial dysfunction. Nevertheless, there are alternative pathways that tumor cells can use to preserve the cytosolic pool of acetyl-coA, such as the conversion of citrate derived from the tricarboxylic acid cycle by the ATP citrate lyase (53, 54) and from glucose, which is also energy producing. However, the glucose-dependent synthesis of lipids was significantly reduced after ST1326 treatment. This effect could be the consequence of both increased anaerobic glycolysis typical of c-myc-overexpressing cells and ST1326-induced mitochondrial toxicity, determining a loss of mitochondrial functions. Thus we suppose that the acetyl-CoA generated in the mitochondrion by salvage pathways, such as from pyruvate, may be exported by CACT independently of ATP citrate lyase (55) and may be sufficient for supporting transformation. Thus CACT inhibition is Figure 6 . Myc-induced lymphomagenesis prevention by in vivo ST1326 treatment and in vivo and ex vivo effect of ST1326 on spleen tissues and on myc-overexpressing B cells. A) Therapeutic potential of ST1326 on transgenic models of murine lymphomagenesis. Eµ-myc mice spontaneously develop B-cell lymphomas within the 14th to16th week of age. A total of 53 mice were divided into two groups and treated from the 4th week with vehicle or with ST1326 30 mg/kg/day for 21 consecutive days. Overall survival was determined by Kaplan-Meier survival curves, which showed a significant delay in the onset of lymphomas in treated mice vs control (CTR) mice, and the difference in terms of disease-free survival was statistically significant (P = .01) by the twosided Mantel-Cox log-rank test. The black bar indicates the length of treatment. B) Hematoxylin and eosin (H&E) staining and immunohistochemistry for B220 antigen on spleen tissues. The ST1326 treatment partially reestablished the normal spleen microscopic architecture in Eµ-myc mice and reduced the anomalous presence of B cells in the red pulp and lymphatic nodules. The pictures were taken at ×2.5 magnification for H&E and B220 staining (central column) (scale bars correspond with 100 μm) and at ×10 magnification for B220 staining (right column) (bars correspond with 25 μm). Images were representative of triplicate samples. C) Cytotoxic effect of ST1326 5 μM on B cells purified from Eµ-myc and wild-type mice after 72 hours of treatment, calculated with Trypan blue exclusion assay. We assumed the mean percentage of viability of control cells obtained from triplicate as reference (100%) and then calculated the relative percentage of viability in ST1326-treated cells for all experiments. The different sensitivity to ST1326 of Eµ-myc B cells compared with wild-type B cells was statistically significant (P = .01). All P values were calculated using a two-sided Student t test.
likely to be effective against cancer cell growth by impinging the export of acetyl-CoA.
CACT inhibition and CPT1A specificity are the major differences between ST1326 and etomoxir. Indeed, the treatment with etomoxir did not show similar cytotoxic properties and lipid accumulation (Supplementary Figure 4 , available online) on Raji cells. The cytotoxic and selective activities of ST1326 described above in in vitro studies were also confirmed in vivo in transgenic Eµ-myc mice, a murine model of Burkitt's lymphoma. Indeed, the treatment induced a statistically significant delay or an escape in the onset of lymphomas. The sensitivity to ST1326 is dependent on c-myc overexpression, as documented by the rescue of the normal spleen structure in treated Eµ-myc mice and by the higher sensitivity of B-cells derived from transgenic mice with respect to those derived from wild-type mice. Altogether, the in vivo results demonstrated a strong efficacy of ST1326 in preventing c-myc-mediated lymphomagenesis, and this might be explained by the fact that c-myc overexpression is sufficient for increasing the cellular sensitivity to the cytotoxic action of ST1326.
This study also had some limitations. Indeed, in regard to aiming to target the carnitine-acyltransferase system for therapeutic applications, an important issue is the selectivity of ST1326 for the CPT1A isoform and the simultaneous coinhibition of CACT. Still, it has to be clarified whether CACT activity is blocked upon ST1326 treatment also in cells expressing other CPT1 isoforms. Moreover, another important point that needs to be clarified is how CPT1A and/or CACT inhibition may differentially contribute to the inhibition of the carnitine-acyltransferase system. To this aim, it may be useful the study of the effect of ST1326 in cells derived from the already established CPT1A knockout mouse model (56) . Finally, a major limitation of the above described approach is that the effect of the treatment is evaluated in vivo on the prevention of the tumor onset rather than the cure of developed tumors. This aspect needs to be assayed in future studies aiming to define if the targeting of FA metabolism and de novo lipogenesis may represent an efficient anticancer strategy. In this scenario, ST1326 might offer a new therapeutic approach, particularly in the management of tumors in which the lipogenic phenotype is sustained by c-myc overexpression.
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